Genentech, Inc. et al v. Sanofi-Aventis Deutschland GMBH et al

Filing 622

Final JUDGMENT and Certification pursuant to Federal Rule of Civil Procedure 54(b) (SI, COURT STAFF) (Filed on 4/21/2011) Modified on 4/21/2011 (ys, COURT STAFF).

1
2
3
4
5

IN THE UNITED STATES DISTRICT COURT

6

FOR THE NORTHERN DISTRICT OF CALIFORNIA

7
8

GENENTECH, INC., et al.,

9
United States District Court
For the Northern District of California

10
11
12

No. C 08-4909 SI; No. C 09-4919 SI

Plaintiffs,

FINAL JUDGMENT AND
CERTIFICATION PURSUANT TO
FEDERAL RULE OF CIVIL
PROCEDURE 54(b)

v.
SANOFI-AVENTIS DEUTSCHLAND GMBH,
Defendant.

/

13
14

Finding that there is no just reason for delay, and pursuant to Federal Rule of Civil Procedure

15

54(b), the Court enters final judgment of non-infringement of the patents-in-suit as to Rituxan® and

16

Avastin® in favor of Genentech and Biogen Idec. and against Sanofi-Aventis Deutschland GMBH.

17

This is a final, appealable judgment.

18
19

IT IS SO ORDERED AND ADJUDGED.

20
21
22
23
24
25
26
27
28

Dated: April 21, 2011
SUSAN ILLSTON
United States District Judge